{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,16]],"date-time":"2026-10-16T18:31:37Z","timestamp":1792175497276,"version":"4.4.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"3","license":[{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,5,1]],"date-time":"2025-05-01T00:00:00Z","timestamp":1746057600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","cysticfibrosisjournal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Cystic Fibrosis"],"published-print":{"date-parts":[[2025,5]]},"DOI":"10.1016\/j.jcf.2024.11.011","type":"journal-article","created":{"date-parts":[[2024,12,6]],"date-time":"2024-12-06T16:07:43Z","timestamp":1733501263000},"page":"466-468","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis"],"prefix":"10.1016","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0009-0004-7247-7016","authenticated-orcid":false,"given":"Angela","family":"Metcalf","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stacey L.","family":"Martiniano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6172-4465","authenticated-orcid":false,"given":"Scott D.","family":"Sagel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6465-8846","authenticated-orcid":false,"given":"Michael V.","family":"Zaretsky","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7507-9337","authenticated-orcid":false,"given":"Edith T.","family":"Zemanick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1588-4852","authenticated-orcid":false,"given":"Jordana E.","family":"Hoppe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jcf.2024.11.011_bib0001","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2024.116155","article-title":"Fetal drug exposure after maternally administered CFTR modulators Elexacaftor\/Tezacaftor\/Ivacaftor in a rat model","volume":"171","author":"Li","year":"2024","journal-title":"Biomed Pharmacother"},{"issue":"4","key":"10.1016\/j.jcf.2024.11.011_bib0002","doi-asserted-by":"crossref","first-page":"725","DOI":"10.1016\/j.jcf.2021.12.004","article-title":"Drug exposure to infants born to mothers taking elexacaftor, tezacaftor, and ivacaftor","volume":"21","author":"Collins","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.011_bib0003","doi-asserted-by":"crossref","DOI":"10.3389\/fmed.2023.1274303","article-title":"Maternal, newborn and breast milk concentrations of elexacaftor\/tezacaftor\/ivacaftor in a F508del heterozygous woman with cystic fibrosis following successful pregnancy","volume":"10","author":"Ripani","year":"2023","journal-title":"Front Med"},{"issue":"1","key":"10.1016\/j.jcf.2024.11.011_bib0004","article-title":"Prospectively evaluating maternal and fetal outcomes in the era of CFTR modulators: the MAYFLOWERS observational clinical trial study design","volume":"9","author":"Jain","year":"2022","journal-title":"BMJ Open Respir Res"},{"issue":"3","key":"10.1016\/j.jcf.2024.11.011_bib0005","doi-asserted-by":"crossref","first-page":"402","DOI":"10.1016\/j.jcf.2021.03.006","article-title":"Maternal and fetal outcomes following elexacaftor-tezacaftor-ivacaftor use during pregnancy and lactation","volume":"20","author":"Taylor-Cousar","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.011_bib0006","doi-asserted-by":"crossref","first-page":"1074","DOI":"10.1016\/j.jcf.2022.10.004","article-title":"Congenital bilateral cataracts in newborns exposed to elexacaftor-tezacaftor-ivacaftor in utero and while breast feeding","volume":"21","author":"Jain","year":"2022","journal-title":"J Cyst Fibros"},{"key":"10.1016\/j.jcf.2024.11.011_bib0007","doi-asserted-by":"crossref","DOI":"10.1016\/j.jcf.2017.06.007","article-title":"Meconium ileus in cystic fibrosis","volume":"16","author":"Sathe","year":"2017","journal-title":"J Cyst Fibros"},{"issue":"4","key":"10.1016\/j.jcf.2024.11.011_bib0008","doi-asserted-by":"crossref","first-page":"721","DOI":"10.1016\/j.jcf.2022.04.005","article-title":"A case report of CFTR modulator administration via carrier mother to treat meconium ileus in a F508del homozygous fetus","volume":"21","author":"Szentpetery","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"5","key":"10.1016\/j.jcf.2024.11.011_bib0009","doi-asserted-by":"crossref","first-page":"835","DOI":"10.1016\/j.jcf.2021.03.018","article-title":"Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy","volume":"20","author":"Fortner","year":"2021","journal-title":"J Cyst Fibros"},{"issue":"485","key":"10.1016\/j.jcf.2024.11.011_bib0010","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aau7531","article-title":"In utero and postnatal VX-770 administration rescues multiorgan disease in a ferret model of cystic fibrosis","volume":"11","author":"Sun","year":"2019","journal-title":"Sci Transl Med"},{"issue":"8","key":"10.1016\/j.jcf.2024.11.011_bib0011","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.157229","article-title":"utero and postnatal ivacaftor\/lumacaftor therapy rescues multiorgan disease in CFTR-F508del ferrets","volume":"9","author":"Evans","year":"2024","journal-title":"JCI Insight"},{"key":"10.1016\/j.jcf.2024.11.011_bib0012","doi-asserted-by":"crossref","DOI":"10.1016\/S1569-1993(24)00167-X","article-title":"CF Ferrets exposed to in utero ivacaftor do not develop lens abnormalities","author":"Taylor-Cousar","year":"2024","journal-title":"J Cyst Fibros"},{"issue":"7","key":"10.1016\/j.jcf.2024.11.011_bib0013","doi-asserted-by":"crossref","first-page":"1015","DOI":"10.7326\/L23-0112","article-title":"Treatment of fetal cystic fibrosis with cystic fibrosis transmembrane conductance regulator modulation therapy","volume":"176","author":"Blumenfeld","year":"2023","journal-title":"Ann Intern Med"},{"issue":"2","key":"10.1016\/j.jcf.2024.11.011_bib0014","doi-asserted-by":"crossref","first-page":"136","DOI":"10.1159\/000530261","article-title":"Prenatal cystic fibrosis transmembrane conductance regulator modulator therapy: a promising way to change the impact of cystic fibrosis","volume":"50","author":"G\u00f3mez-Montes","year":"2023","journal-title":"Fetal Diagn Ther"},{"issue":"4","key":"10.1016\/j.jcf.2024.11.011_bib0015","doi-asserted-by":"crossref","first-page":"558","DOI":"10.1016\/j.jcf.2022.05.014","article-title":"Editorial \u2013 The ethical implications of treating a pregnant woman to benefit the fetus","volume":"21","author":"Bennett","year":"2022","journal-title":"J Cyst Fibros"},{"issue":"6","key":"10.1016\/j.jcf.2024.11.011_bib0016","doi-asserted-by":"crossref","first-page":"1622","DOI":"10.1002\/ppul.26954","article-title":"International disparities in diagnosis and treatment access for cystic fibrosis","volume":"59","author":"Guo","year":"2024","journal-title":"Pediatr Pulmonol"}],"container-title":["Journal of Cystic Fibrosis"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018435?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1569199324018435?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,7]],"date-time":"2025-11-07T22:09:32Z","timestamp":1762553372000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1569199324018435"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5]]},"references-count":16,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2025,5]]}},"alternative-id":["S1569199324018435"],"URL":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.011","relation":{},"ISSN":["1569-1993"],"issn-type":[{"value":"1569-1993","type":"print"}],"subject":[],"published":{"date-parts":[[2025,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcomes of prenatal use of elexacaftor\/tezacaftor\/ivacaftor in carrier mothers to treat meconium ileus in fetuses with cystic fibrosis","name":"articletitle","label":"Article Title"},{"value":"Journal of Cystic Fibrosis","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jcf.2024.11.011","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 European Cystic Fibrosis Society. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}